Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Frederick Lansigan
Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax Treated CLL in Routine Clinical Practice
Clinical Cancer Research
Cancer Research
Oncology
Diffuse Large B-Cell Lymphoma With Primary Treatment Failure: Ultra-High Risk Features and Benchmarking for Experimental Therapies
American Journal of Hematology
Hematology
Related publications
Unfavourable Risk Factor Control After Coronary Events in Routine Clinical Practice
BMC Cardiovascular Disorders
Cardiovascular Medicine
Cardiology
How to Approach CLL in Clinical Practice
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Venetoclax–Obinutuzumab Elicits High Response Rates in CLL
Cancer Discovery
Oncology
Disclosing Clinical Adverse Events to Patients: Can Practice Inform Policy?
Health Expectations
Environmental
Public Health
Occupational Health
Venetoclax‐induced Tumour Lysis Syndrome in Acute Myeloid Leukaemia
British Journal of Haematology
Hematology
Pcn84 - Total Cost of Care and Budget Impact for Patients With CLL Treated With Venetoclax
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Improved Clinical Outcomes and Physical Activity in Patients With Rheumatoid Arthritis Treated With Originator Adalimumab in Routine Clinical Practice
International Journal of Clinical Rheumatology
Rheumatology
Determinants of Virological Outcome and Adverse Events in African Children Treated With Paediatric Nevirapine Fixed-Dose-Combination Tablets
AIDS
Infectious Diseases
Allergy
Immunology
Illuminating Aberrant mRNA Events in CLL
Cancer Discovery
Oncology
